Results 41 to 50 of about 40,738 (244)

Interpretation of results obtained using real-time fluorescence PCR based on multiplex PCR fragment analysis for ABCB1 tri-allele

Sichuan jingshen weisheng, 2022
ObjectiveTo resolve the problems related to the abnormal interpretations of real-time fluorescence polymerase chain reaction （PCR） results for tri-allele， to formulate the interpretation methods of real-time fluorescence PCR by referring to multiplex PCR
Zhang Yan, Meng Zhuocheng, Xing Huan, Cui Xiaohua, Yang Liu, Zheng Xuan, Dai Zunxiao   +6 more
doaj   +1 more source

Towards the clinical implementation of pharmacogenetics in bipolar disorder. [PDF]

, 2014
BackgroundBipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide.
A Berghofer, A Heils, A Koski, A Serretti, A Serretti, A Serretti, A Szczepankiewicz, A Yu, AA Nierenberg, AK Malhotra, AL Zackrisson, B Alsina, B Kremeyer, C Cordon-Cardo, C Kawanishi, C O’Dushlaine, C Sears, CA Grimes, CC Zai, CE Begley, CH Chen, DA Mrazek, DE Adkins, DJ Smith, DK Hall-Flavin, DK Hall-Flavin, DL Braff, E Lessard, E Schaeffeler, EB Binder, EB Brown, EG Jonsson, EJ Peters, EK Green, EM Penas-Lledo, EM Penas-Lledo, EN Smith, ER Mardis, Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, F Asztely, F Benedetti, F Czerwensky, F Holsboer, F Mamdani, FJ Gonzalez, FJ McMahon, FM Daray, FP Bymaster, FP Guengerich, FR Sallee, G Shaltiel, G Turecki, GE Simon, GENDEP Investigators, MARS Investigators, STAR*D Investigators, GR Lewin, GS Malhi, GS Sachs, H Pei, HA Garriock, HK Kroemer, I Johansson, IC Gray, J Brockmoller, J de Leon, J de Leon, J de Leon, J de Leon, J Kirchheiner, J Kirchheiner, J Thome, J Winner, JA Engelman, JA Johnson, JA Lieberman, JC Ballenger, JC Chambers, JC Stingl, JE Kootstra-Ros, JE Sarginson, JK Rybakowski, JK Rybakowski, JM Beaulieu, John R Kelsoe, JP Zhang, JP Zhang, JR Kelsoe, JS Leeder, JT Groves, K Herrlin, K Hodgson, K Yoshii, KG Mountjoy, KL Kopnisky, KR Crews, KW Lobello, L Bertilsson, L Michelon, L Tondo, LA Smith, LN Yatham, LV Kessing, M Adli, M Dmitrzak-Weglarz, M Gex-Fabry, M Ingelman-Sundberg, M Man, M Ramsjo, M Sanford, M Tseng, M Uhr, MA Kohli, MA Martin, MD Ritchie, ME van den Akker-van Marle, MH Tsai, Michael J McCarthy, MJ Arranz, MJ McCarthy, MJ Neville, ML Dahl, Naji C Salloum, OL de Klerk, OV Olesen, P Grof, P Huezo-Diaz, P Sklar, PS Klein, Psychiatric GWAS Consortium Bipolar Disorder Working Group, R Calati, R Hashimoto, RA Philibert, RC Kessler, RH Perlis, RH Perlis, RH Perlis, RH Perlis, RH Weisler, RJ Loos, RM Hirschfeld, RM Post, RS Seelan, S Horstmann, S Kapur, S Kapur, S Mallal, S Paddock, S Steinberg, S Ulrich, SC Sim, SG Leckband, SH Sindrup, SI Hung, SJ Gardiner, SL McElroy, Susan G Leckband, SV Ambudkar, T Bremer, T Masui, T Rau, T Ritchie, T Suppes, TD Gould, TE Klein, TL Horvath, V De Luca, VL Ellingrod, W Steimer, WB Denny, WH Chung, YF Lin, YF Zou, Z Wang, Z Wang   +172 more
core   +3 more sources

The ABCB1 Transporter in Alzheimer’s Disease [PDF]

Clinical & Experimental Pharmacology, 2014
ABC genes, especially ABCB1 (ATP-binding cassette, sub-family B (MDR/TAP), member 1; Doxorubicin resistance; Multidrug resistance 1; Multidrug resistance protein 1; P-glycoprotein 1; P glycoprotein 1/ multiple drug resistance 1;P-gp) (7q21.12), ABCC1 (9q31.1), ABCG2 (White1) (21q22.3), and other genes of this family encode proteins
López-Muñoz, F., Cacabelos, Ramón
openaire   +2 more sources

Effects of Polyphenols on P-Glycoprotein (ABCB1) Activity [PDF]

Pharmaceutics, 2021
P-glycoprotein (Pgp, ABCB1) is a member of one of the largest families of active transporter proteins called ABC transporters. Thanks to its expression in tissues with barrier functions and its broad substrate spectrum, it is an important determinant of the absorption, metabolism and excretion of many drugs.
Kuljeet Singh, Szabolcs Tarapcsák, Zsuzsanna Gyöngy, Zsuzsanna Ritter, Gyula Batta, Rosevalentine Bosire, Judit Remenyik, Katalin Goda   +7 more
openaire   +3 more sources

Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects

Медицинский совет, 2020
Background: despite well-studied safety profile of dabigatran its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD).
A. I. Skripka, P. O. Bochkov, K. A. Akmalova, R. V. Shevchenko, P. M. Krupenin, V. V. Kogay, A. I. Listratov, A. S. Krainyaya, D. A. Napalkov, O. S. Gurinovich, A. A. Sokolova, V. V. Fomin, D. A. Sychev   +12 more
doaj   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Hatziieremia, S., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Mountford, J.C.   +4 more
core   +1 more source

Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1

Pharmaceuticals, 2023
2-Ethyl-6-methyl-3-hydroxypyridine succinate (EMHPS, Mexidol) is an original antioxidant and an anti-ischemic drug with the possibility of wide applications in the complex therapy of diseases, accompanied by the development of oxidative stress and ischemia; for example, ischemic stroke, chronic cerebral ischemia, and chronic heart failure.
Aleksey V. Shchulkin, Pelageya D. Erokhina, Anna V. Goncharenko, Pavel Yu. Mylnikov, Ivan V. Chernykh, Yulia V. Abalenikhina, Maria S. Kotliarova, Elena N. Yakusheva   +7 more
openaire   +3 more sources

Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells

Frontiers in Pharmacology, 2021
The emergence of multidrug resistance (MDR) has been a major issue for effective cancer chemotherapy as well as targeted therapy. One prominent factor that causes MDR is the overexpression of ABCB1 transporter.
Zhuo-Xun Wu, Yuqi Yang, Jing-Quan Wang, Wen-Min Zhou, Junyu Chen, Yi-Ge Fu, Ketankumar Patel, Zhe-Sheng Chen, Jian-Ye Zhang   +8 more
doaj   +1 more source

Dual gene activation and knockout screen reveals directional dependencies in genetic networks. [PDF]

, 2018
Understanding the direction of information flow is essential for characterizing how genetic networks affect phenotypes. However, methods to find genetic interactions largely fail to reveal directional dependencies. We combine two orthogonal Cas9 proteins
Biton, Anne, Blau, James A, Boettcher, Michael, Fu, Haian, Kampmann, Martin, Markegard, Evan, McCormick, Frank, McManus, Michael T, Mo, Xiulei, Tian, Ruilin, Wagner, Ryan T, Wu, David, Zaitlen, Noah   +12 more
core   +2 more sources

Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function [PDF]

Biochemical Pharmacology, 2009
The effectiveness of chemotherapeutic treatment is usually limited by the overexpression of adenosine triphosphate binding cassette (ABC) transporters, which mediate multidrug resistance (MDR) by acting as efflux pumps to remove chemotherapeutic agents from MDR cancer cells. Thus, the inhibition of ABC transporters may represent a promising strategy to
Chun-ling, Dai, Yong-ju, Liang, Li-ming, Chen, Xu, Zhang, Wen-jing, Deng, Xiao-dong, Su, Zhi, Shi, Chung-pu, Wu, Charles R, Ashby, Shin-ichi, Akiyama, Suresh V, Ambudkar, Zhe-sheng, Chen, Li-wu, Fu   +12 more
openaire   +2 more sources